Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations

CONCLUSION: For patients with EGFR20ins mutation, compared to chemotherapy, ICI+Chemo prolongs PFS, and after chemotherapy progression, bevacizumab combined with chemotherapy seems better than Furmonertinib-based targeted therapy on PFS. For HER2-20ins mutation, Beva+Chemo may be a better choice.PMID:38567147 | PMC:PMC10985835 | DOI:10.3389/fonc.2024.1357231

Source: Cancer Control - April 3, 2024 Category: Cancer & Oncology Authors: Jiaqi Li Mengqing Xie Ruiying Zhao Huiping Qiang Qing Chang Jialin Qian Haijiao Lu Yinchen Shen Yuchen Han Chunxia Su Tianqing Chu Source Type: research